Ratio Based Biomarkers for the Prediction of Cancer Survival


The AKT pathway plays a key role in the regulation of cellular survival, apoptosis, and protein translation and has been shown to have prognostic significance in a number of cancers.  Recently, the inventors have identified several functions of the AKT pathway in certain cancers, such as extrahepatic cholangiocarcinoma (EHCC).

The NCI seeks partners to license or co-develop this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.  Utilizing multiplex tissue immunoblotting, the inventors have demonstrated that PTEN expression, PTEN/p-AKT ratios, and PTEN/p-mTOR ratios can predict the survival of cancer patients.  These biomarkers may provide useful diagnostic information for cancer patients as well as identify patients appropriate for mTOR analog-based chemotherapy or agents directed against AKT.



Potential Commercial Applications: Competitive Advantages:
  • Diagnostic and Prognostic tool to detect the presence of cancer and predict the relative cancer survival rate for a subject with cancer
  • Method of identifying patients appropriate for therapies targeted to the AKT pathway
  • A kit for detecting cancer associated proteins in a sample
 
  • Useful to predict cancer patient survival


Development Stage:
Prototype

Inventors:

Stephen Hewitt (NCI)  ➽ more inventions...

Joon-Yong Chung (NCI)  ➽ more inventions...


Intellectual Property:
U.S. Provisional Application No. 61/114,501

Publications:
Chung J, et al. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. PMID 19147772

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-025-2009
Updated: Mar 29, 2018